Abstract:
The present invention relates to a sentinel lymph node marker comprising albumin to which a radioactive isotope, one or more dyes selected from near-infrared ray absorbing dyes, and a visible ray absorbing dye are coupled, a preparation method thereof, a kit for preparing the same for multi-mode imaging the sentinel lymph node, and a multi-mode imaging method of the sentinel lymph node using the same. The sentinel lymph node marker of the present invention has a long retention time at a lymph node and enables multi-mode imaging, and thus it is possible to precisely check the sentinel lymph node without a skin incision by ex vivo imaging through a near-infrared image and/or gamma ray image, and it is possible to precisely check the location of the sentinel lymph node with the naked eye when used in conjunction with surgery for removing the checked sentinel lymph node.
Abstract:
A kit and a composition comprising Herceptin, an antibody binding specifically to HER2, based on detecting Herceptin-sensitive HER2-overexpressing cells are provided for diagnosing cancer. A method of detecting Herceptin-sensitive HER2-overexpressing cells using the same is also provided.
Abstract:
The present invention relates to: radioisotope labeled folic acid conjugate human serum albumin specific to tumor and lymph tissues, and to a preparation method thereof; a disposable kit for images of a tumor and sentinel lymph node which comprises a mixture in which methylene diphosphonic acid, ascorbic acid and stannous chloride are added to folic acid conjugate thiol human serum albumin, and a preparation method of the disposable kit; and a composition for imaging tumor cells metastasized to a sentinel lymph node and comprising radioisotope labeled folic acid conjugate human serum albumin, and an imaging method. According to the present invention, useful effects are derived, of reducing the possibility of a false-negative, and providing a sentinel lymph node marker which further increases the accuracy of biopsies of sentinel lymph nodes because it has characteristics of an active marker specifically binding to a tumor as well as characteristics of a passive marker that remains in a lymph node for a long period of time.
Abstract:
A kit and a composition comprising Herceptin, an antibody binding specifically to HER2, based on detecting Herceptin-sensitive HER2-overexpressing cells are provided for diagnosing cancer. A method of detecting Herceptin-sensitive HER2-overexpressing cells using the same is also provided.